# US 2025/0367278 A1 · Variant strain-based coronavirus vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367278 A1
- Document ID: US20250367278A1
- Status: Published application
- Kind: A1
- Application number: 19/294,594
- Filed: 2025-08-08
- Published: 2025-12-04
- Earliest claimed: 2021-01-15
- Assignees: ModernaTX, Inc.
- Applicants: ModernaTX, Inc.
- Inventors: Andrea Carfi; Guillaume Stewart-Jones; Hamilton Bennett; Kai Wu; Darin Edwards; Gwo-Yu Chuang; David Reid
- Web page: https://patentgrep.com/patent/US20250367278A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.

## Claims

### Claim at position 1

-54. (canceled)

### Claim 55

A pharmaceutical composition comprising a messenger RNA (mRNA) comprising a nucleotide sequence encoding a SARS-CoV-2 Spike(S) protein, wherein the SARS-CoV-2 S protein comprises: (a) at least 10 of the following mutations as compared to SEQ ID NO:18: A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F; and (b) an amino acid sequence that is at least 97% identical to SEQ ID NO:33, or to an immunogenic fragment thereof; wherein the mRNA comprises 1-methyl-pseudouridine substitutions at one or more uridine positions of the mRNA.

### Claim 56 (depends on 55)

The pharmaceutical composition of claim 55, wherein the nucleotide sequence is at least 90% identical to SEQ ID NO:32.

### Claim 57 (depends on 55)

The pharmaceutical composition of claim 55, wherein the nucleotide sequence is at least about 90% identical to SEQ ID NO:32.

### Claim 58 (depends on 55)

The pharmaceutical composition of claim 55, wherein the mRNA comprises 1-methyl-pseudouridine substitutions at all uridine positions of the mRNA.

### Claim 59 (depends on 55)

The pharmaceutical composition of claim 55, wherein the mRNA comprises one or more of the following: (a) a 5′-cap that comprises 7 mG(5′)ppp(5′) N1mpNp; (b) a poly(A) sequence comprising 50 to 250 A nucleotides; (c) a 5′-UTR that comprises a modified human alpha-globin 5′-UTR; and (d) a 3′-UTR.

### Claim 60 (depends on 55)

The pharmaceutical composition of claim 55, wherein the mRNA is formulated in lipid nanoparticles.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the mRNA is present in an amount within a range of about 25 μg to about 100 μg.

### Claim 62 (depends on 60)

The pharmaceutical composition of claim 60, wherein the mRNA is present in an amount of about 10 μg.

### Claim 63 (depends on 60)

The pharmaceutical composition of claim 60, wherein the mRNA is present in an amount of about 30 μg.

### Claim 64

A pharmaceutical composition comprising a messenger RNA (mRNA) comprising a nucleotide sequence encoding a SARS-CoV-2 Spike(S) protein, wherein the SARS-CoV-2 S protein comprises: (a) at least 10 of the following mutations as compared to SEQ ID NO:18: Δ69-70, T95I, G142D, ΔY144, R190S, K417N, N439K, E484K, S477N, T478K, N501Y, D614G, H655Y, and P681H; and (b) an amino acid sequence that is at least 97% identical to SEQ ID NO:14, or to an immunogenic fragment thereof; wherein the mRNA comprises 1-methyl-pseudouridine substitutions at one or more uridine positions of the mRNA.

### Claim 65 (depends on 64)

The pharmaceutical composition of claim 64, wherein the nucleotide sequence is at least 90% identical to SEQ ID NO:13.

### Claim 66 (depends on 64)

The pharmaceutical composition of claim 64, wherein the nucleotide sequence is at least about 90% identical to SEQ ID NO:13.

### Claim 67 (depends on 64)

The pharmaceutical composition of claim 64, wherein the mRNA comprises 1-methyl-pseudouridine substitutions at all uridine positions of the nucleotide sequence.

### Claim 68 (depends on 64)

The pharmaceutical composition of claim 64, wherein the mRNA is formulated in lipid nanoparticles.

### Claim 69 (depends on 68)

The pharmaceutical composition of claim 68, wherein the mRNA is present in an amount within a range of about 25 μg to about 100 μg.

### Claim 70 (depends on 68)

The pharmaceutical composition of claim 68, wherein the mRNA is present in an amount of about 10 μg.

### Claim 71 (depends on 68)

The pharmaceutical composition of claim 68, wherein the mRNA is present in an amount of about 30 μg.

### Claim 72 (depends on 55)

A method of eliciting an immune response against SARS-CoV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 55 in an effective amount to induce the immune response.

### Claim 73 (depends on 64)

A method of eliciting an immune response against SARS-CoV-2 in a human subject, comprising administering to the human subject the pharmaceutical composition of claim 64 in an effective amount to induce the immune response.
